Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.30 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16245778 | 0.91 | TP53 (0.41) | GRIN2DGRIN2AGRIN2BGRIN2CTP53 | |
| SCHEMBL16245736 | 0.83 | GABRA1 (0.46) | TP53TSHRGABRA1GABRB2CYP2C9 | |
| SCHEMBL16245758 | 0.81 | GRIN2D (0.43) | GRIN2DGRIN2AGRIN2BGRIN2CHIF1A | |
| SCHEMBL16245798 | 0.80 | TSHR (0.44) | TP53TSHRGABRA1GABRB2 | |
| SCHEMBL28038237 | 0.74 | TP53 (0.39) | GRIN2DGRIN2AGRIN2BGRIN2CTP53 | |
| SCHEMBL16245721 | 0.72 | GRIN2D (0.43) | GRIN2DGRIN2AGRIN2BGRIN2CHIF1A | |
| SCHEMBL16245795 | 0.72 | LMNA (0.44) | TP53TSHR | |
| SCHEMBL16245691 | 0.72 | GRIN2D (0.33) | GRIN2DGRIN2AGRIN2BGRIN2CGABRA1 | |
| SCHEMBL16245727 | 0.71 | GRIN2D (0.42) | GRIN2DGRIN2AGRIN2BGRIN2CHIF1A | |
| SCHEMBL29671369 | 0.71 | TSHR (0.44) | TP53TSHRGABRA1GABRB2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2994448-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2019-07-31 | — | — | EP | claimed |
| US-9656938-B2 | Organic compounds | GIVAUDAN S.A. (CH) | 2017-05-23 | — | — | US | claimed |
| US-20160075627-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2016-03-17 | — | — | US | claimed |
| EP-2994448-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2016-03-16 | — | — | EP | claimed |
| CN-105189432-A | Improvements in or relating to organic compounds | GIVAUDAN SA | 2015-12-23 | — | — | CN | claimed |
| WO-2014180952-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2014-11-13 | — | — | WO | claimed |
| EP-3581554-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2022-04-20 | — | — | EP | disclosed |
| US-10457891-B2 | Organic compounds | GIVAUDAN S.A. (CH) | 2019-10-29 | — | — | US | disclosed |
| US-10457891-B2 | Organic compounds | GIVAUDAN S.A. (CH) | 2019-10-29 | — | — | US | disclosed |
| EP-2994448-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2019-07-31 | — | — | EP | disclosed |
| US-20180251706-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2018-09-06 | — | — | US | disclosed |
| US-9988592-B2 | Organic compounds | Givaudan, S.A. (CH) | 2018-06-05 | — | — | US | disclosed |
| US-9988592-B2 | Organic compounds | Givaudan, S.A. (CH) | 2018-06-05 | — | — | US | disclosed |
| US-9656938-B2 | Organic compounds | GIVAUDAN S.A. (CH) | 2017-05-23 | — | — | US | disclosed |
| US-20160075627-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2016-03-17 | — | — | US | disclosed |
| US-20160075627-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2016-03-17 | — | — | US | disclosed |
| EP-2994448-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2016-03-16 | — | — | EP | disclosed |
| CN-105189432-A | Improvements in or relating to organic compounds | GIVAUDAN SA | 2015-12-23 | — | — | CN | disclosed |
| WO-2014180952-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2014-11-13 | — | — | WO | disclosed |
| WO-2014180952-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075627-A1 | ORGANIC COMPOUNDS | AOX1, TYR, ALK | GRIN2D 3286/4885GRIN2A 3578/4885GRIN2B 3280/4885 |
| US-20180251706-A1 | ORGANIC COMPOUNDS | AOX1, TYR, ALK | GRIN2D 3286/4885GRIN2A 3578/4885GRIN2B 3280/4885 |
| US-10457891-B2 | Organic compounds | AOX1, TYR, ALK | GRIN2D 3286/4885GRIN2A 3578/4885GRIN2B 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.